Stents are used to keep arteries open during heart surgery. The Endeavour stent is known as a drug-eluting stent, which is coated with a drug that helps to prevent the re-clogging of arteries after the procedure.
The Endeavor stent combines Abbott’s patented drug Zotarolimus, Medtronic’s Driver Coronary Stent platform, and Biocompatibles PC Polymer into a drug-eluting stent system.
The Zotarolimus manufacturing process has been co-developed by Abbott and ScinoPharm, and ScinoPharm will continue to supply the drug substance for the Endeavor stent.
Drug-eluting stents have been shown to be superior to traditional bare-metal stents and can reduce the rate of repeat procedures due to re-clogging of arteries in patients with coronary disease.
The worldwide market for drug-eluting stents is approximately $5.5 billion, and is expected to grow at rapid pace. The size of the market outside of the US, excluding Japan, is between $ 1 billion and $1.5 billion.